Market capitalization | $407.20m |
Enterprise Value | $200.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 22.23 |
P/S ratio (TTM) P/S ratio | 45.19 |
P/B ratio (TTM) P/B ratio | 1.10 |
Revenue growth (TTM) Revenue growth | -14.16% |
Revenue (TTM) Revenue | $9.01m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
11 Analysts have issued a Autolus Therapeutics plc forecast:
11 Analysts have issued a Autolus Therapeutics plc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 9.01 9.01 |
14%
14%
|
|
Gross Profit | -29 -29 |
807%
807%
|
|
EBITDA | -259 -259 |
54%
54%
|
EBIT (Operating Income) EBIT | -267 -267 |
53%
53%
|
Net Profit | -238 -238 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 647 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.